Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Argus Health
McKinsey
Moodys
Daiichi Sankyo
Fish and Richardson
Harvard Business School
UBS
Merck

Generated: December 17, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HEXAMINOLEVULINATE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Hexaminolevulinate Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00052637 Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder Cancer Completed National Cancer Institute (NCI) Phase 3 RATIONALE: Diagnostic procedures such as cystoscopy may improve the ability to detect cancer and to determine the extent of disease. PURPOSE: Diagnostic trial to compare the effectiveness of cystoscopy using hexyl 5-aminolevulinate and two light sources in detecting carcinoma in situ in patients who have bladder cancer.
NCT00052637 Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder Cancer Completed Photocure Phase 3 RATIONALE: Diagnostic procedures such as cystoscopy may improve the ability to detect cancer and to determine the extent of disease. PURPOSE: Diagnostic trial to compare the effectiveness of cystoscopy using hexyl 5-aminolevulinate and two light sources in detecting carcinoma in situ in patients who have bladder cancer.
NCT00285701 Early Detection of Polyps and Colon Cancer by Fluorescence Imaging - a Dose-finding Study Completed KARL STORZ Endoscopy-America, Inc. Phase 1/Phase 2 Patients referred for colon inspection (colonoscopy) due to suspicion of colon polyps/cancer will receive local administration of hexaminolevulinate (HAL) prior to colon inspection. Blue light illumination will induce red fluorescence of polyps and tumours, improving detection of the polyps and tumors. Different HAL doses will be tested to find the optimal image conditions. Tolerability measurements will be performed to ensure patient safety.
NCT00285701 Early Detection of Polyps and Colon Cancer by Fluorescence Imaging - a Dose-finding Study Completed Photocure Phase 1/Phase 2 Patients referred for colon inspection (colonoscopy) due to suspicion of colon polyps/cancer will receive local administration of hexaminolevulinate (HAL) prior to colon inspection. Blue light illumination will induce red fluorescence of polyps and tumours, improving detection of the polyps and tumors. Different HAL doses will be tested to find the optimal image conditions. Tolerability measurements will be performed to ensure patient safety.
NCT00369018 A Dose-finding Study of MAL and HAL Photodynamic Therapy of Cervical Premalignant Lesions. Completed Photocure Phase 1/Phase 2 The study will determine the best drug (MAL or HAL) dosage for photodynamic therapy of cervical precancerous lesions (dysplasia) in women that are referred for conisation (surgery).
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Hexaminolevulinate Hydrochloride

Condition Name

Condition Name for Hexaminolevulinate Hydrochloride
Intervention Trials
Bladder Cancer 3
Cervical Intraepithelial Neoplasia 2
Colorectal Cancer 2
Colon Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Hexaminolevulinate Hydrochloride
Intervention Trials
Cervical Intraepithelial Neoplasia 3
Urinary Bladder Neoplasms 3
Carcinoma in Situ 3
Colorectal Neoplasms 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Hexaminolevulinate Hydrochloride

Trials by Country

Trials by Country for Hexaminolevulinate Hydrochloride
Location Trials
Germany 5
Norway 4
France 2
Netherlands 1
United States 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Hexaminolevulinate Hydrochloride
Location Trials
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Hexaminolevulinate Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Hexaminolevulinate Hydrochloride
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Hexaminolevulinate Hydrochloride
Clinical Trial Phase Trials
Completed 6
Withdrawn 2
Terminated 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Hexaminolevulinate Hydrochloride

Sponsor Name

Sponsor Name for Hexaminolevulinate Hydrochloride
Sponsor Trials
Photocure 8
GE Healthcare 2
KARL STORZ Endoscopy-America, Inc. 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Hexaminolevulinate Hydrochloride
Sponsor Trials
Industry 12
Other 2
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
US Army
Express Scripts
Chinese Patent Office
QuintilesIMS
UBS
Merck
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.